Abstract
Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large randomized trial (EOI 80831/MRC B002) comparing two different regimens of chemotherapy in patients with osteosarcoma.
Methods. Patients with biopsy-proven osteosarcoma localized and metastatic, age 40 years or younger, were randomized to receive either two-drug treatment with doxorubicin/cisplatin (DOX 25 mg m-2 day-1 × 3 + DDP 100 mg m-2 on day 1 q 3 weeks × 6 courses) or three-drug treatment comprising high-dose methotrexate (HDMTX 8 mg m-2 administered every 4.5 weeks × 4 courses) given 10 days before DOX/DDP.
Results. Twenty-four patients with metastatic disease received the two-drug arm treatment and 13 received three-drug treatment. Despite chance imbalance in numbers, there were no major differences in age, sex, primary site or performance status. Baseline alkaline phosphatase (AP) was elevated more frequently (96 vs 42%) in the two-drug arm. Twenty-one of 24 patients in the two-drug arm and 11/13 patients in the three-drug arm had evaluable primary tumors concurrent with metastases. Respective clinical response rates for the two- and three-drug arms were 48% and 40% for primary tumors, and 33% and 55% for metastases. Respective survivals at 2 and 4 years were 36% and 9% for the two-drug arm, and 69% and 52% for the three-drug arm, and survival was better for patients with normal AP at presentation. When adjusted for AP, survival was not significantly different between the two treatments (hazard ratio 0.52, 95% confidence interval 0.22–1.23, p = 0.14). There were three long-term survivors among the metastatic patients, all of whom received the three-drug therapy.
Discussion. It is likely that random bias in the population (small numbers, imbalance in size of groups, uneven distribution of AP) accounts for the difference in outcome favoring the three-drug treatment in patients with metastatic disease. More reliance can be placed on the finding that disease-free and overall survival in the adjuvant component of this study (Bramwell et al., J Clin Oncol 1992; 10: 1579–91) were better after two-drug treatment.
Full Text
The Full Text of this article is available as a PDF (603.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bacci G., Picci P., Briccoli A., Avella M., Ferrari S., Femino F. P., Monti C., Ruggieri P., Rizzente A. G., Casadei R. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori. 1992 Jun 30;78(3):200–206. doi: 10.1177/030089169207800311. [DOI] [PubMed] [Google Scholar]
- Bacci G., Picci P., Ruggieri P., Mercuri M., Avella M., Capanna R., Brach Del Prever A., Mancini A., Gherlinzoni F., Padovani G. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990 Jun 1;65(11):2539–2553. doi: 10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
- Bleyer W. A. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977 Jun;4(2):87–101. doi: 10.1016/s0305-7372(77)80007-8. [DOI] [PubMed] [Google Scholar]
- Bramwell V. H., Burgers M., Sneath R., Souhami R., van Oosterom A. T., Voûte P. A., Rouesse J., Spooner D., Craft A. W., Somers R. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992 Oct;10(10):1579–1591. doi: 10.1200/JCO.1992.10.10.1579. [DOI] [PubMed] [Google Scholar]
- Bramwell V. H. The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol Hematol. 1995 Aug;20(1-2):61–85. doi: 10.1016/1040-8428(94)00145-j. [DOI] [PubMed] [Google Scholar]
- Carter S. K. The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials. 1980 Spring;3(1):29–36. [PubMed] [Google Scholar]
- Delepine N., Delepine G., Cornille H., Brion F., Arnaud P., Desbois J. C. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res. 1995 Mar-Apr;15(2):489–494. [PubMed] [Google Scholar]
- Graf N., Winkler K., Betlemovic M., Fuchs N., Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994 Jul;12(7):1443–1451. doi: 10.1200/JCO.1994.12.7.1443. [DOI] [PubMed] [Google Scholar]
- Jaffe N., Frei E., 3rd, Traggis D., Watts H. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977 Jan;39(1):45–50. doi: 10.1002/1097-0142(197701)39:1<45::aid-cncr2820390109>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
- Jaffe N., Frei E., 3rd, Watts H., Traggis D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat Rep. 1978 Feb;62(2):259–264. [PubMed] [Google Scholar]
- Meyers P. A., Heller G., Healey J. H., Huvos A., Applewhite A., Sun M., LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993 Mar;11(3):449–453. doi: 10.1200/JCO.1993.11.3.449. [DOI] [PubMed] [Google Scholar]
- Rosen G., Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep. 1982 Sep;66(9):1687–1697. [PubMed] [Google Scholar]
- Winkler K., Beron G., Delling G., Heise U., Kabisch H., Purfürst C., Berger J., Ritter J., Jürgens H., Gerein V. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329–337. doi: 10.1200/JCO.1988.6.2.329. [DOI] [PubMed] [Google Scholar]